INTRAVENOUS ZOLEDRONIC ACID IN PREVENTING SUBSEQUENT OSTEOPOROTIC FRACTURES

静脉注射唑来膦酸预防后续骨质疏松性骨折

• 批准号: 7377438
• 负责人: RICHARD C HENDERSON
• 金额: $ 0.32万
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7377438
• 关键词: INTRAVENOUS; ZOLEDRONIC; ACID; PREVENTING; SUBSEQUENT

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to determine whether an investigational drug with the name zoledronic acid, (a bisphosphonate) plus, vitamin D2, vitamin D and elemental calcium carbonate given after surgical repair on an acute hip fracture, is more effective in reducing the rate of all subsequent bone fractures compared to vitamin D2, vitamin D and elemental calcium carbonate alone, during a two year period of time. This study will also attempt to determine the effect of zoledronic acid on quality of life, physical activities of daily living, body pain, and medical costs (exploratory endpoints).

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子弹和调查员（PI）可能已经从其他NIH来源获得了主要资金，因此可以在其他清晰的条目中代表。列出的机构适用于该中心，这不一定是调查员的机构。这项研究的目的是确定具有佐洛甲酸名称（双膦酸盐）的研究药物是否在手术修复后进行急性髋部骨折后进行手术修复后给予的碳酸钙和碳酸钙的碳酸钙是否在降低所有随后的骨骼D2和元素D2的时间范围内更有效。这项研究还将试图确定唑来膦酸对生活质量，日常生活，身体疼痛和医疗费用（探索性终点）的影响。